Suggested Remit - To appraise the clinical and cost-effectiveness of tagraxofusp within its marketing authorisation for treating patients with blastic plasmacytoid dendritic cell neoplasm
Status In progress
Process STA 2018
ID number 1556

Provisional Schedule

Expected publication 24 March 2021

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
28 November 2019 This appraisal will be rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that this drug will consequently not be eligible to receive interim CDF funding from the date of marketing authorisation as no NICE recommendation will be made at that point. For information, this appraisal is now anticipated to begin during early May 2020 when we will write to you about how you can get involved.
07 October 2019 (10:00) Scoping workshop (Manchester)
16 August 2019 - 16 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress, Referred 17 October 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance